Understanding the role of beta-1,6-glucan in the cell wall of a harmful fungus
Official title: Solving the puzzle of beta-1,6-glucan in the cryptococcal cell wall
Funded at Washington University · NIH-11209714 · Data updated 2026-11-12
This study is looking at a part of a fungus called Cryptococcus neoformans that can be harmful to people with weakened immune systems, like those with HIV, to find ways to make better treatments for infections caused by it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | June 6, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $773,053 |
| NIH project number | 1R01AI192892-01 |
| Project ID | NIH-11209714 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with compromised immune systems, particularly those living with HIV or other conditions that increase susceptibility to fungal infections.
✕Less likely to help
Patients who are not immunocompromised or do not have a history of Cryptococcus neoformans infections may not benefit from this research.
What this research studies
This research investigates the cell wall of Cryptococcus neoformans, a fungus that poses a significant health risk, particularly to individuals with weakened immune systems, such as those living with HIV. The focus is on understanding beta-1,6-glucan, a crucial component of the cell wall that helps maintain its structure and integrity. By exploring how this glucan is synthesized, the research aims to identify potential vulnerabilities that could be targeted by antifungal therapies. This could lead to the development of more effective treatments for infections caused by this pathogen.
Why it matters
Potential benefit: If successful, this research could lead to new antifungal therapies that are effective against Cryptococcus neoformans infections.
How similar studies have gone: Previous research has shown success in targeting fungal cell wall components for antifungal therapy, indicating that this approach has potential.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Doering, Tamara L — Washington University
- Study coordinator: Doering, Tamara L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.